Browse the evidence

Glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide) produce statistically significant weight loss in overweight or obese patients with type 2 diabetes compared to placebo, with no significant difference in efficacy between the different GLP-1 agonists or dosages.

If you have Type 2 Diabetes and are overweight, GLP-1 receptor agonist medications (like Exenatide or Liraglutide) are clinically proven to help you lose weight compared to a placebo. The amount of weight loss is modest (around 1-1.6 kg over 6 months) but consistent across different types of these drugs. This is significant because even small weight losses can improve survival and health outcomes in diabetes. These medications are injectable and may cause temporary stomach issues, but they are more effective for weight loss than many other common diabetes drugs that cause weight gain.

Short sleep duration (habitual or acute) is associated with reduced serum leptin and elevated serum ghrelin, which likely increases appetite and contributes to increased body mass index (BMI).

If you are struggling with weight management or excessive hunger, prioritize getting 7-8 hours of sleep. Short sleep (less than 7 hours) biologically increases your hunger hormones (ghrelin) and decreases your fullness hormones (leptin), making it significantly harder to resist high-calorie foods. Fixing your sleep schedule is a foundational step before expecting diet changes to stick.

Tirzepatide at 15 mg and maximum tolerated dose (MTD) provides superior weight loss efficacy compared to semaglutide (2.4 mg and MTD) in non-diabetic adults with obesity, but this benefit is offset by significantly higher rates of gastrointestinal side effects and treatment discontinuation.

If you are a non-diabetic adult with obesity seeking maximum weight loss, tirzepatide at 15mg or MTD is statistically more effective than semaglutide. However, you must accept a higher risk of gastrointestinal side effects and a higher chance of stopping the medication due to those side effects. Discuss your tolerance for potential side effects versus the desire for maximum weight loss with your provider.

Subcutaneous semaglutide (up to 2.4 mg weekly) produces a mean weight reduction of 11.85% in adults with obesity without diabetes compared to placebo, though it significantly increases the risk of gastrointestinal adverse events and treatment discontinuation.

If you have obesity without diabetes, semaglutide (up to 2.4 mg weekly) can help you lose about 12% of your body weight, which is significantly more than placebo. However, you must be prepared for a high likelihood of temporary stomach issues like nausea or diarrhea. These side effects are common but usually mild and go away. You will also need to follow a reduced-calorie diet and exercise plan alongside the medication for best results.

Semaglutide significantly reduces Major Adverse Cardiovascular Events (MACE) and hospitalization for heart failure (HHF) risk, while Tirzepatide significantly reduces HHF risk, offering cardiovascular protection beyond weight loss.

If you have obesity and cardiovascular disease or heart failure, Semaglutide and Tirzepatide are not just weight loss drugs; they offer proven cardiovascular protection. Semaglutide reduces the risk of major heart events, and Tirzepatide reduces hospitalizations for heart failure. These benefits are independent of, but additive to, the weight loss achieved.

Weight loss triggers compensatory metabolic adaptations (hormonal and energy expenditure changes) that promote weight regain, making long-term maintenance difficult.

Expect that maintaining weight loss will be biologically challenging. Your body will fight back with increased hunger and decreased energy expenditure. This is normal and not your fault. Long-term success requires ongoing strategies to manage these biological drivers, such as regular self-monitoring and possibly higher protein intake to combat hunger hormones.

The weight loss efficacy of Tirzepatide is dose-dependent and increases with longer duration of treatment.

If you are taking Tirzepatide, sticking with the treatment for a longer duration and reaching the higher maintenance doses (like 15mg) will result in more significant weight loss than lower doses. The drug's effectiveness scales with the dose.

Circadian disruption, such as that caused by shift work or sleep restriction, leads to insulin resistance, hypoleptinemia, and increased risk of obesity and type 2 diabetes.

Prioritize consistent sleep duration and quality. If you must work shifts, try to maintain a consistent sleep schedule even on days off, and expose yourself to bright light during your 'day' and darkness during your 'night' to help reset your internal clock.

Obesity accelerates the loss of pancreatic beta-cell function and insulin sensitivity through ectopic adipose expansion, systemic low-grade inflammation, and lipotoxicity, leading to Type 2 Diabetes Mellitus (T2DM).

Obesity is not just about weight; it actively damages the body's ability to use insulin and produce it via inflammation and fat accumulation in organs like the liver and pancreas. Managing obesity is critical to preventing or delaying T2DM, but it requires addressing metabolic health, not just scale weight.

Maintaining a body mass index (BMI) between 18.5-25 kg/m2 and avoiding adult weight gain reduces the risk of developing cancers of the oesophagus (adenocarcinoma), colorectum, breast (postmenopausal), endometrium, and kidney.

Aim to keep your BMI between 18.5 and 25. Avoid gaining significant weight during adulthood. This is a key strategy to reduce the risk of several common cancers, including breast, colorectal, and endometrial cancer.

Alcohol consumption increases the risk of cancers of the oral cavity, pharynx, oesophagus, liver, and breast; intake should not exceed 2 units/d.

If you drink alcohol, limit your intake to no more than 2 units per day. This helps reduce the risk of several cancers, including those of the mouth, throat, liver, and breast.

A higher proportion of slow-twitch (ST) muscle fibers is associated with greater insulin sensitivity and accelerated glucose uptake, whereas a shift toward fast-twitch (FT) fibers is linked to insulin resistance.

Your muscle fiber composition influences how well your body handles insulin. Slow-twitch fibers are more efficient at glucose uptake. While you cannot completely rewrite your genetics, endurance training can stimulate molecular pathways (like PGC-1 and PPAR-α) that enhance the oxidative capacity of your muscles, effectively making them more 'slow-twitch' in function and improving insulin sensitivity. This is particularly relevant if you are at risk for type 2 diabetes or obesity.

Endurance exercise training increases the abundance of PGC-1 and PPAR-α proteins in skeletal muscle, which promotes a slow-twitch (ST) phenotype and protects against insulin resistance and obesity.

Engaging in regular endurance exercise (like running or cycling) triggers molecular changes in your muscles, specifically increasing PGC-1 and PPAR-α. These proteins help shift your muscle's metabolic profile toward a more efficient, slow-twitch state, which improves your body's ability to manage blood sugar and resist obesity. You don't need to know your exact fiber type to benefit; consistent endurance work drives these adaptations.

High consumption of sugar-sweetened beverages (SSBs) causes an increased risk of coronary heart disease (CHD) and type 2 diabetes, independent of body mass index (BMI).

Stop drinking sugar-sweetened beverages. Even if you maintain your weight, the sugar in these drinks independently raises your risk of heart disease and type 2 diabetes. Choose water, unsweetened tea, or coffee instead.

High consumption of glycemic load causes an increased risk of type 2 diabetes.

Reduce your glycemic load by choosing whole, unprocessed foods. High glycemic load foods like white bread and sugary drinks increase the risk of type 2 diabetes. Opt for vegetables, fruits, and whole grains.

Type 2 diabetes should be managed as a component of Metabolic Dysfunction Syndrome (MDS) rather than solely as a hyperglycemic disorder, requiring holistic protection of target organs against all MDS-related metabolic disorders.

Do not treat Type 2 Diabetes as just a 'blood sugar problem.' Your risk of organ damage comes from the combination of high blood sugar, high blood pressure, high lipids, and excess weight. Effective management requires addressing all these metabolic factors together to protect your heart, kidneys, and eyes, rather than focusing on glucose alone.

In older men, 20 g of whey protein is sufficient to maximize myofibrillar protein synthesis (MPS) at rest, but resistance exercise creates anabolic resistance that requires 40 g of whey protein to further elevate MPS rates above the 20 g threshold.

If you are over 60 and doing resistance training, 20g of high-quality protein (like whey) might not be enough to maximize muscle building after your workout. Try increasing your post-workout protein to 40g. At rest, 20g is likely sufficient, but exercise increases your body's demand for protein to trigger muscle synthesis.

Higher fiber and lower glycemic load (GL) in vegetables are associated with stronger inverse relationships with weight change, whereas fiber and GL content in fruits do not significantly modify the weight loss association.

For weight management, prioritize vegetables with high fiber and low glycemic load (like leafy greens and cruciferous veggies). For fruits, the type (fiber/GL) matters less; all whole fruits seem to support weight loss, likely due to other beneficial compounds. Avoid fruit juice.

Higher dietary glycemic index (GI) and glycemic load (GL) are robustly associated with an increased risk of incident type 2 diabetes (T2D) in adults initially in good health.

To lower your risk of type 2 diabetes, prioritize foods with a lower glycemic index and load. This means choosing carbohydrates that digest more slowly, rather than just reducing the total amount of carbs. The evidence suggests that the quality of carbohydrates, specifically their impact on blood sugar rise, is a significant predictor of diabetes risk in healthy adults.

Triple hormone receptor agonist retatrutide (1-12 mg weekly) significantly reduces liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), achieving near-maximal reduction (~80%) at 24 weeks with high doses (8-12 mg).

For patients with MASLD, high-dose retatrutide (8-12 mg weekly) offers a highly effective treatment to significantly reduce liver fat, often normalizing it within 24 weeks. This hormonal intervention addresses the root metabolic drivers of liver fat accumulation more potently than current GLP-1 mono-agonists.

Higher circulating or adipose tissue levels of the dairy fat biomarkers pentadecanoic acid (15:0), heptadecanoic acid (17:0), and trans-palmitoleic acid (t16:1n-7) are associated with a significantly lower incidence of type 2 diabetes.

High levels of specific fatty acids (15:0, 17:0, and t16:1n-7) in your blood or fat tissue, which serve as biomarkers for dairy fat consumption, are linked to a lower risk of developing type 2 diabetes. This suggests that moderate consumption of dairy products may be metabolically beneficial, contrary to the general advice to avoid all saturated fats.

Obese, insulin-resistant individuals exhibit a defective (reduced) thermic effect of food, specifically for glucose, which may contribute to weight gain or impaired weight loss, though it cannot explain the majority of excess body weight.

If you are obese and insulin-resistant, your body may burn slightly fewer calories from food (50-150 kcal/day) than a lean person. While this makes weight loss slightly harder, it is not the main reason for obesity. Focus on sustainable caloric deficits and improving insulin sensitivity through exercise and diet quality rather than blaming a 'broken metabolism'.

Intramuscular factors, specifically changes in Androgen Receptor (AR) protein content and p70S6K phosphorylation, are significant predictors of muscle hypertrophy, explaining more variance than systemic hormones.

Muscle growth is driven by local signals within the muscle, such as Androgen Receptor content and p70S6K phosphorylation, rather than systemic hormone levels. Consistent resistance training upregulates these local factors, which are the true drivers of hypertrophy.

The acute post-exercise increase in Interleukin-6 (IL-6) is correlated with muscle hypertrophy, but it does not add predictive value beyond local muscle factors like AR and p70S6K.

The inflammatory response to exercise, specifically IL-6, is correlated with muscle growth. However, this is likely a byproduct of local muscle adaptation rather than the primary driver. Focus on training consistency rather than trying to manipulate inflammation.